[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652666":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":15,"responsibleParty":35,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":18,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Izmir Ataturk Training and Research Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"late-onset gestational diabetes mellitus",null,"In routine screening tests with Fasting Blood Glucose Test (FBG) at 32-34 weeks of gestation, late-onset GDM will be defined by FBG ≥5.1 mmol\u002FL (92mg\u002Fdl), which is routinely checked in fasting blood.",{"label":13,"type":10,"description":14,"interventionNames":10},"control","In routine screening tests with Fasting Blood Glucose Test (FBG) at 32-34 weeks of gestation, control group will be defined by FBG \\\u003C5.1 mmol\u002FL (92mg\u002Fdl), which is routinely checked in fasting blood.",[16],{"facility":17,"status":18,"city":19,"state":20,"zip":21,"country":22,"countryCode":10,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"İzmir Katip Çelebi Atatürk Training and Research","RECRUITING","Izmir","Karabağlar","35360","Turkey (Türkiye)",{"type":24,"coordinates":25},"Point",[26,27],27.13838,38.41273,{"lat":27,"lon":26},[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Yasin Ateş","CONTACT","05343325171","yasinates48@gmail.com",{"type":36,"investigatorFullName":31,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","assistant doctor","100652666","are-there-any-clinical-benefits-to-screening-for-late--onset-gestational-diabetes-mellitus-100652666",false,"NCT07776314","Are There Any Clinical Benefits to Screening for Late -Onset Gestational Diabetes Mellitus?\"","Inclusion Criteria:\n\n* Gestational Age: Confirmed singleton pregnancy between 32+0 and 34+6 weeks of gestation based on the last menstrual period (LMP) and\u002For first-trimester crown-rump length (CRL) ultrasound measurement.\n\nFollow-up: Intention and willingness to deliver at the study hospital and complete all planned follow-up visits until the end of the postpartum period.\n\nInformed Consent: Voluntary agreement to participate in the study evidenced by signed written informed consent.\n\nExclusion Criteria:\n\n* Multifetal pregnancies (e.g., twins, triplets) Fetal Anomalies Pre-gestational Chronic Diseases Protocol Non-compliance \u002F Loss to Follow-up Preterm Birth \u002F Preterm Labor",true,"FEMALE","18 Years","45 Years",{"count":49,"type":50},128,"ESTIMATED","OBSERVATIONAL","This study aims to screen women who have a negative Gestational diabetes mellitus (GDM) result in routine screening tests or who have never had it with the Fasting Blood Glucose Test (FBG) at 32-34 weeks of gestation to diagnose late-onset GDM with routine FBG ≥5.1 mmol\u002FL (92mg\u002Fdl) in fasting blood, and to investigate its connection with perinatal and maternal outcomes, hoping to inform about late-stage GDM.",[54,55,56],"Pregnancy in Diabetes","Pregnancy","Pregnancy Outcomes",[58,59,60],"late-onset gestationel diabetes mellitus","benefits to screening for late -onset Gestational Diabetes Mellitus","Gestational Diabetes Mellitus","2026-08-17",{"date":63,"type":64},"2026-08-20","ACTUAL",{"date":66,"type":64},"2025-03-13",{"date":68,"type":50},"2026-11-10",{"name":5,"class":6},1]